Innovation Theaters
* These are not official programs of the American College of Rheumatology.
Dual Perspectives in Psoriatic Disease Management: Zero Disease Activity in One or More Domains
Innovation Theater A
Developed and offered by UCB, Inc.
Learn how UCB is committed to patients with BIMZELX!
Exhibit Hall Theater A and UCB Booth #1101, McCormick Place Convention Center
Developed and offered by UCB, Inc.
An Expert Review of the Evolving Clinical Profile of SAPHNELO® (anifrolumab-fnia) and Emerging Evidence
Innovation Theater B
Developed and offered by AstraZeneca.
Autoimmune-Associated Interstitial Lung Disease: The Patient Journey and Physician Perspective
Innovation Theater A
Developed and offered by Boehringer Ingelheim Pharmaceuticals, Inc.
IgG4-RD in Focus: Clinical Presentation, Diagnosis, and Management
Innovation Theater B
Developed and offered by Amgen.
The JAK-STAT Odyssey: Past Discoveries, Present Understanding, and Future Horizons
Innovation Theater A
Developed and offered by Pfizer, Inc.
A Product Theater for Zepbound® (tirzepatide) Injection Including an Affordability Solution for Taltz® (ixekizumab) Patients
Innovation Theater B
Developed and offered by Eli Lilly and Company.
Reaching Further: Exploring Long-term Data on a Treatment with a Well Documented Safety Profile for Adults with Active PsA
Innovation Theater A
Developed and offered by AbbVie, Inc.
Early Initiation of Treatment: Evolving Management of Lupus and LN
Innovation Theater A
Developed and offered by GSK.
YOUR ROLE IN THE CAR T RESEARCH ERA: The Rheumatologist’s Guide to Who, When, and How
Innovation Theater B
Developed and offered by Bristol Myers Squibb
AVISE CTD: A Decade of Validation Driving Lupus Diagnostic Accuracy, Seronegative RA Biomarker Innovation, and Novel T-Cell Biomarkers for Lupus
Innovation Theater A
Developed and offered by Exagen.
Discover a Treatment Option for Macrophage Activation Syndrome (MAS)
Innovation Theater B
Developed and offered by Sobi.
Dermatomyositis in Focus: What Do We Know about Immunoglobulin Therapy?
Innovation Theater A
Developed and offered by Octapharma
Advancing Care in Lupus Nephritis: Exploring the Evolving Landscape
Innovation Theater B
Developed and offered by Genentech
A Targeted Treatment Approach for Eosinophilic Granulomatosis with Polyangiitis (EGPA)
Innovation Theater A
Developed and offered by AstraZeneca.
The Intersection Where Rheumatology Meets Dermatology
Innovation Theater B
Developed and offered by Biogen.